Decentralized Clinical trials have become increasingly prevalent in the biotech and biopharmaceutical industries.
Decentralized Clinical trials have become increasingly prevalent in the biotech and biopharmaceutical industries. Experts suggest the value of DCTs will increase by 9.8% between 2023 to 2029. Decentralized Clinical trials are cost effective and offer many benefits to researchers and participants alike, which is likely the cause of their increased usage. However, there are also some risks involved. To address this, the FDA released draft guidance to regulate DCTs and ensure participant privacy and data is protected. The guidance covers data collection and storage, investigator and sponsor responsibilities, and more.
DISCOVER MORE
Mastering the Difference: Monitoring and Auditing
Pharmaceutical research sponsors must make sure they follow both Monitoring and Auditing rules during their studies - so what's the difference?
Understanding the Distinctions: QA vs. QC
While these terms are sometimes used interchangeably, it is important to understand their distinctions and the specific protocols associated with each area.
We Invest In Our Employees
At FDAQRC, we understand that the best business practices must start with our employees.
National Volunteer Month
During the month of April, FDAQRC encouraged employees to donate or volunteer. Read about the impact our team made!
Applying Lean Methodology Practically
Lean Methodology is a way of optimizing the people, resources, effort, and energy of your organization toward creating value for the customer.
How to Generate Consistent Work as A Consultant
Generating consisting work seems to be a common struggle our network is seeing. Here are a few tips to set yourself up for success as a consultant and increase your number of projects.
Strategies for Combating Education Bias in Regulatory Workspaces
This downloadable poster elaborates on the problems surrounding education bias in the biopharmaceutical industry.